Anti-apoptotic effect of esculin on dopamine-induced cytotoxicity in the human neuroblastoma SH-SY5Y cell line

Neuropharmacology

Volumn 53, Issue 6, 2007, Pages 724-732

  Zhao, Da Long ^a,b   Zou, Li Bo ^b   Lin, Sheng ^a   Shi, Jian Gong ^a   Zhu, Hai Bo ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Dopamine; Esculin; Parkinson's disease; Reactive oxygen species

Indexed keywords

APOPTOSIS INDUCING FACTOR; CASPASE 3; CYTOCHROME C; DOPAMINE; ESCULIN; GLUTATHIONE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; FRAXINUS; FRAXINUS SIELBODDIANA; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; CYTOCHROMES C; DOPAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCULIN; EXCITATORY AMINO ACIDS; GLUTATHIONE; HUMANS; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; SUPEROXIDE DISMUTASE; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 35148895156     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.07.017     Document Type: Article

References (39)

1. Barzilai A., Melamed E., and Shirvan A. Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease?. Cell. Mol. Neurobiol. 21 (2001) 215-235
2. Cohen J.J., Duke R.C., Fadok V.A., and Sellins K.S. Apoptosis and programmed cell death in immunity. Annu. Rev. Immunol. 10 (1992) 267-293
3. Cory S., and Adams J.M. The Bcl-2 family, regulators of cellular life-or-death switch. Nat. Rev. Cancer 2 (2002) 647-656
4. Di-Monte D., Sandy M.S., Elkstrom G., and Smit M.T. Comparative studies on the mechanisms of paraquat and 1-methyl-4-phenylpyridine (MPP+) cytotoxicity. Biochem. Biophys. Res. Commun. 137 (1986) 303-309
5. Duan W., Zhu X., Ladenheim B., Yu Q.S., Guo Z.J., Oyler R.G., Cutler J.L., Cadet N.H., and Greig M.P. P53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann. Neurol. 52 (2002) 597-606
6. Emdadul H.M., Masato A., Youichirou H., Ikuko M., Ken-ichi T., and Norio O. Apoptosis-inducing neurotoxicity of dopamine and its metabolites viareactive quinone generation in neuroblastoma cells. Biochim. Biophys. Acta 1619 (2003) 39-52
7. Gomez S.C., Ferrer I., Santidrian A.F., Barrachina M., Gil J., and Ambrosio S. Dopamine induces autophagic cell death and α-synuclein increase in human neuroblastoma SH-SY5Y cells. J. Neurosci. Res. 73 (2003) 341-350
8. Gorman A.M., Orrenius S., and Ceccateli S. Apoptosis in neuronal cells: role of caspases. Neuroreport 9 (1998) 49-55
9. Graeber M.B., and Moran L.B. Mechanisms of cell death in neurodegenerative diseases: fashion, fiction, and facts. Brain Pathol. 12 (2002) 385-39
10. Han B.S., Homg H.S., Choi W.S., Markelonis G.J., Oh T.H., and Oh Y.J. Caspase-dependent and -independent cell death pathways in primary cultures of mesencephalic dopaminergic neurons after neurotoxin treatment. J. Neurosci. 23 (2003) 5069-5078
11. Hartmann A., Hunot S., Michel P.P., Mureil M.P., Vyas S., and Faucheux B.A. Caspase-3, a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 2875-2880
12. Holtz W.A., and O'Malley K.L. Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons. J. Biol. Chem. 278 (2003) 19367-19377
13. Hong S.J., Dawson T.M., and Dawson V.L. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol. Sci. 25 (2004) 259-264
14. Jellinger K.A. Cell death mechanisms in Parkinson's disease. J. Neural Trans. 107 (2000) 1-29
15. Junn E., and Mouradian M.M. Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases. J. Neurochem. 78 (2001) 374-383
16. Kehrer J.P., and Smith C.V. Free radicals in biology: sources, reactivities, and roles in the etiology of human diseases. In: Frei B. (Ed). Natural Antioxidants in Human Health and Disease (1994), Academic Press, San Diego 25-62
17. Kitamura Y., Kamoshima W., Shimohama S., Nomura Y., and Taniguchi T. Nitric oxide donor-induced p53 sensitive cell death in enhanced by Bcl-2 reduction in human neuroblastoma cells. Neurochem. Int. 32 (1998) 93-102
18. Kluck R.M., Martin S.J., Zhou J.S., Green D.R., and Newmeyer D.D. Cytochrome c activation of CPP32-like proteolysis plays a critical role in a Xenopus cell-free apoptosis system. EMBO J. 16 (1996) 4639-4649
19. Lai C.T., and Yu P.H. Dopamine- and l-h-3,4-dihydroxyphenylalanine hydrochloride (l-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem. Pharmacol. 53 (1997) 363-372
20. Li H., and Dryhurst G. Oxidative metabolites of 5-S-cysteinyldopamine inhibit the pyruvate dehydrogenase complex. J. Neural Trans. 108 (2001) 1363-1374
21. Li H., Shen X.M., and Dryhurst G. Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: potential relevance to the pathogenesis of Parkinson's disease. J. Neurochem. 71 (1998) 2049-2062
22. Lin S., Wang S.J., Liu M.T., Gan M.L., Li S., Yang Y.C., Wang Y.H., He W.Y., and Shi J.G. Glycosides from the stem bark of Fraxinus sieboldiana. J. Nat. Prod. 70 5 (2007) 817-823
23. Lopes U.G., Erhardt P., Yao R., and Cooper G.M. P53-dependent induction of apoptosis by proteasome inhibitors. J. Biol. Chem. 272 (1997) 12893-12896
24. Majno G., and Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am. J. Pathol. 146 (1995) 3-15
25. Mandir A.S. A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism. J. Neurochem. 83 (2002) 186-192
26. Mattson M.P. Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell Biol. 1 (2000) 120-129
27. Miyashita T., Krajewski S., Krajewski M., Wang H.G., Lin H.K., Liebermann D.A., Hoffman B., and Reed J.C. Tumor suppressor p53 is a regulator of Bcl-2 and Bax gene expression in vitro and in vivo. Oncogene 9 (1994) 1799-1805
28. Mizuno Y., Yoshino H., Ikebe S., Hattori N., Kobayashi T., Shimoda-Matsubayashi S., Matsumine H., and Kondo T. Mitochondrial dysfunction in Parkinson's disease. Ann. Neurol. 44 (1998) S99-S109
29. Nicholls D.G., and Budd S.L. Mitochondria and neuronal survival. Physiol. Rev. 80 (2000) 315-360
30. Porter A.G., and Janicke R.U. Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6 (1999) 99-104
31. Rijk M.C., Tzourio C., Breteler M.M., Dartigues J.F., Amaducci L., and Lopez-Pousa S. Prevalence of Parkinsonism and Parkinson's disease in Europe: the europarkinson collaborative study. European community concerted action on the epidemiology of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 62 (1997) 10-15
32. Schapira A.H., Gu M., Taanman J.W., Tabrizi S.J., Seaton T., Cleeter M., and Cooper J.M. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann. Neurol. 44 (1998) S89-S98
33. Seaton T.A., Cooper J.M., and Schapria A.H. Free radical scavengers protect dopaminergic cell line from apoptosis induced by mitochondrial complex I toxins. Brain Res. 777 (1997) 110-118
34. Shen Y., and White E. P53-dependent apoptosis pathways, Adv. Cancer Res. 82 (2001) 55-84
35. Sidell K.R., Amamath V., and Montine T.J. Dopamine thioethers in neurodegeneration. Curr. Top. Med. Chem. 1 (2001) 519-527
36. Spencer J.P., Whiteman M., Jenner P., and Halliwell B. 5-SCysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons. J. Neurochem. 81 (2002) 122-129
37. Stokes A.H., Hasting T.G., and Vrane K.E. Cytotoxic and genotoxicpotential of dopamine. J. Neurosci. Res. 55 (1999) 659-665
38. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
39. Whitehead R.E., Ferrer J.V., Javitch J.A., and Justice J.B. Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. J. Neurochem. 76 (2001) 1242-1251